ABVC
NASDAQABVC Biopharma
$1.45
-0.57 (-28.22%)
2026-07-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$35.1M
P/E Ratio
N/A
52W Low
52W High
$0.90
$3.40
Volume
511K
Analyst Rating
Hold
Target: $2
12 Analyst Ratings
Strong Buy
0
Buy
0
Hold
12
Sell
0
Price Target Range
Low: $2
Avg: $2
High: $2
About ABVC Biopharma
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II cl...
Employees
16
Website
abvcpharma.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $796K | -898.5% | -$7.9M | -$3.0M |
| 2024 | $510K | -923.3% | -$4.9M | -$1.8M |
| 2023 | $152K | -4439.2% | -$7.8M | -$4.2M |
| 2022 | $970K | -1558.5% | -$16.4M | -$7.3M |
| 2021 | $356K | -3290.1% | -$12.8M | -$7.6M |
| 2026 Q1 | N/A | N/A% | -$1.6M | -$894K |
| 2025 Q4 | -$796K | 376.3% | -$3.6M | -$1.4M |
| 2025 Q3 | $796K | -246.8% | -$2.0M | -$133K |
| 2025 Q2 | N/A | N/A% | -$2.3M | -$894K |
| 2025 Q1 | $2K | -35249.5% | -$842K | -$540K |
| 2024 Q4 | $2K | -16996.8% | $229K | -$494K |
| 2024 Q3 | $389K | -77.7% | -$395K | $172K |
| 2024 Q2 | $117K | -734.2% | -$942K | -$211K |